2024
The PRECEDE consortium: A longitudinal international cohort study of high-risk individuals for the development of pancreatic cancer
Earl J, Zogopoulos G, Bi Y, Brand R, Chung D, Farrell J, Graf J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Paiella S, Permuth J, Rosie C, Simeone D. The PRECEDE consortium: A longitudinal international cohort study of high-risk individuals for the development of pancreatic cancer. Pancreatology 2024, 24: e82-e83. DOI: 10.1016/j.pan.2024.05.206.Peer-Reviewed Original ResearchHigh-risk individualsInternational cohort studyDevelopment of pancreatic cancerCohort studyPancreatic cancerIndividuals
2022
The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.
Zogopoulos G, Bi Y, Brand R, Chung D, Earl J, Farrell J, Graff J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Permuth J, Sears R, Simeone D, Consortium T. The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer. Journal Of Clinical Oncology 2022, 40: e16239-e16239. DOI: 10.1200/jco.2022.40.16_suppl.e16239.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPathogenic germline variantsFamilial pancreatic cancerCancer predisposition genesCohort studyPancreatic cancerClinical dataAnnual surveillanceEffective early detection strategiesHigh-quality clinical dataHigh-risk premalignant lesionsModifiers of riskInternational cohort studyProspective cohort studyEarly-stage diseaseOverall survival rateEarly detection strategiesEarly-stage cancerBlood sample collectionRelevant clinical populationContribution of heritabilityPenetrance of diseaseQuality clinical dataParticipants ages 18Germline testing
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply